ID

30172

Description

Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00462332

Lien

https://clinicaltrials.gov/show/NCT00462332

Mots-clés

Versions (1)
  1. 16/05/2018 16/05/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

16 mai 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Leukemia NCT00462332

Anglais

Eligibility Leukemia NCT00462332

1 Formulaires  
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT00462332
Criteria
Description

Criteria

diagnosis of chronic lymphocytic leukemia (cll)
Description

Chronic Lymphocytic Leukemia

Type de données

boolean

Alias
UMLS CUI [1]
C0023434
advanced or progressive disease with ≥ 2 active clinical signs
Description

Advanced disease | Progressive Disease | Sign or Symptom Quantity

Type de données

boolean

Alias
UMLS CUI [1]
C0679246
UMLS CUI [2]
C1335499
UMLS CUI [3,1]
C3540840
UMLS CUI [3,2]
C1265611
patient characteristics:
Description

Client Characteristics

Type de données

boolean

Alias
UMLS CUI [1]
C0815172
fertile patients must use adequate contraception
Description

Fertility Contraceptive methods

Type de données

boolean

Alias
UMLS CUI [1,1]
C0015895
UMLS CUI [1,2]
C0700589
no positive coomb's test with signs of hemolysis
Description

Exclusion Criteria | Coombs Test Positive | Signs Hemolysis

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C0009961
UMLS CUI [2,2]
C1514241
UMLS CUI [3,1]
C0311392
UMLS CUI [3,2]
C0019054
no active infection
Description

Exclusion Communicable Disease

Type de données

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C0009450
no uncontrolled severe disease
Description

Exclusion Disease Severe Uncontrolled

Type de données

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C0012634
UMLS CUI [1,3]
C0205082
UMLS CUI [1,4]
C0205318
no known hypersensitivity or anaphylactic reactions to murine antibodies or proteins
Description

Exclusion Criteria | Hypersensitivity Murine-Derived Monoclonal Antibodies | Anaphylaxis Murine-Derived Monoclonal Antibodies | Hypersensitivity Murine protein | Anaphylaxis Murine protein

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C2916903
UMLS CUI [3,1]
C0002792
UMLS CUI [3,2]
C2916903
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C1699668
UMLS CUI [5,1]
C0002792
UMLS CUI [5,2]
C1699668
no other malignancies within the past 2 years except for adequately treated malignancies
Description

Exclusion Cancer Other | Exception Malignant Neoplasms Treated

Type de données

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0006826
UMLS CUI [2,3]
C1522326
no significant traumatic injury within the past 4 weeks
Description

Exclusion Traumatic injury

Type de données

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C3263723
no coexisting medical or psychological condition that would limit study compliance
Description

Exclusion Criteria | Medical condition Limiting Protocol Compliance | Mental condition Limiting Protocol Compliance

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0439801
UMLS CUI [2,3]
C0525058
UMLS CUI [3,1]
C3840291
UMLS CUI [3,2]
C0439801
UMLS CUI [3,3]
C0525058
prior concurrent therapy:
Description

Therapeutic procedure

Type de données

boolean

Alias
UMLS CUI [1]
C0087111
see disease characteristics
Description

ID.13

Type de données

boolean

no prior treatment for cll
Description

Exclusion Prior Therapy Chronic Lymphocytic Leukemia

Type de données

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C1514463
UMLS CUI [1,3]
C0023434
no major surgery within the past 4 weeks
Description

Exclusion Major surgery

Type de données

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C0679637
no prior chemotherapy
Description

Exclusion Prior Chemotherapy

Type de données

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C1514457
Retour au début de la page

Similar models

Eligibility Leukemia NCT00462332

1 Formulaires
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT00462332
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Chronic Lymphocytic Leukemia
Item
diagnosis of chronic lymphocytic leukemia (cll)
boolean
C0023434 (UMLS CUI [1])
Advanced disease | Progressive Disease | Sign or Symptom Quantity
Item
advanced or progressive disease with ≥ 2 active clinical signs
boolean
C0679246 (UMLS CUI [1])
C1335499 (UMLS CUI [2])
C3540840 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Fertility Contraceptive methods
Item
fertile patients must use adequate contraception
boolean
C0015895 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Exclusion Criteria | Coombs Test Positive | Signs Hemolysis
Item
no positive coomb's test with signs of hemolysis
boolean
C0680251 (UMLS CUI [1])
C0009961 (UMLS CUI [2,1])
C1514241 (UMLS CUI [2,2])
C0311392 (UMLS CUI [3,1])
C0019054 (UMLS CUI [3,2])
Exclusion Communicable Disease
Item
no active infection
boolean
C2828389 (UMLS CUI [1,1])
C0009450 (UMLS CUI [1,2])
Exclusion Disease Severe Uncontrolled
Item
no uncontrolled severe disease
boolean
C2828389 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,3])
C0205318 (UMLS CUI [1,4])
Exclusion Criteria | Hypersensitivity Murine-Derived Monoclonal Antibodies | Anaphylaxis Murine-Derived Monoclonal Antibodies | Hypersensitivity Murine protein | Anaphylaxis Murine protein
Item
no known hypersensitivity or anaphylactic reactions to murine antibodies or proteins
boolean
C0680251 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C2916903 (UMLS CUI [2,2])
C0002792 (UMLS CUI [3,1])
C2916903 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C1699668 (UMLS CUI [4,2])
C0002792 (UMLS CUI [5,1])
C1699668 (UMLS CUI [5,2])
Exclusion Cancer Other | Exception Malignant Neoplasms Treated
Item
no other malignancies within the past 2 years except for adequately treated malignancies
boolean
C2828389 (UMLS CUI [1,1])
C1707251 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
Exclusion Traumatic injury
Item
no significant traumatic injury within the past 4 weeks
boolean
C2828389 (UMLS CUI [1,1])
C3263723 (UMLS CUI [1,2])
Exclusion Criteria | Medical condition Limiting Protocol Compliance | Mental condition Limiting Protocol Compliance
Item
no coexisting medical or psychological condition that would limit study compliance
boolean
C0680251 (UMLS CUI [1])
C3843040 (UMLS CUI [2,1])
C0439801 (UMLS CUI [2,2])
C0525058 (UMLS CUI [2,3])
C3840291 (UMLS CUI [3,1])
C0439801 (UMLS CUI [3,2])
C0525058 (UMLS CUI [3,3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
ID.13
Item
see disease characteristics
boolean
Exclusion Prior Therapy Chronic Lymphocytic Leukemia
Item
no prior treatment for cll
boolean
C2828389 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C0023434 (UMLS CUI [1,3])
Exclusion Major surgery
Item
no major surgery within the past 4 weeks
boolean
C2828389 (UMLS CUI [1,1])
C0679637 (UMLS CUI [1,2])
Exclusion Prior Chemotherapy
Item
no prior chemotherapy
boolean
C2828389 (UMLS CUI [1,1])
C1514457 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial